SPARC Monoclonal antibody

SPARC Monoclonal Antibody for WB,ELISA

Host / Isotype

Mouse / IgG2a

Reactivity

human and More (1)

Applications

WB,ELISA

Conjugate

Unconjugated

CloneNo.

1A2C1

Cat no : 66426-1-Ig

Synonyms

Basement membrane protein 40, BM 40, ON, Osteonectin, SPARC



Tested Applications

Positive WB detected inA375 cells, human testis tissue, NCCIT cell

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:2000-1:10000
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 2 publications below

Product Information

66426-1-Ig targets SPARC in WB,ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivity human, mouse
Host / Isotype Mouse / IgG2a
Class Monoclonal
Type Antibody
Immunogen SPARC fusion protein Ag7390
Full Name secreted protein, acidic, cysteine-rich (osteonectin)
Calculated molecular weight 35 kDa
Observed molecular weight 38 kDa, 52 kDa
GenBank accession numberBC004974
Gene symbol SPARC
Gene ID (NCBI) 6678
Conjugate Unconjugated
Form Liquid
Purification Method Protein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

SPARC, also known as ON (Osteonectin) or BM-40 (Basement-membrane protein 40), is an extracellular glycoprotein with the calculated molecular mass of 35 kDa and the apparent molecular mass of 40-43 kDa and 50 kDa (PMID: 7495300, 12365801). SPARC belongs to a group of matricellular proteins defined as secreted components that do not contribute directly to the formation of structural elements but serve to modulate cell-matrix interactions and cellular functions (PMID: 7542656; 12231357). SPARC is expressed at high levels in bone tissue, is distributed widely in many other tissues and cell types, and is associated generally with tissues undergoing morphogenesis, remodeling and wound repair (PMID: 10567433). It elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (PMID: 12721366). Altered expression of SPARC has been reported in a variety of cancers, which include breast, ovarian, colorectal, and pancreatic cancer as well as melanoma and glioblastomas (PMID: 18849185).

Protocols

Product Specific Protocols
WB protocol for SPARC antibody 66426-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouseWB

Exp Cell Res

Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2.

Authors - Wei Huang
humanWB

Br J Cancer

Inactivation of 3-hydroxybutyrate dehydrogenase type 2 promotes proliferation and metastasis of nasopharyngeal carcinoma by iron retention.

Authors - Bo Li